Merck & Co. (MRK) Q4 2025 (USD): adj. EPS 2.04 (exp. 2.01), Revenue 16.4bln (exp. 16.20bln)

• Q4 Keytruda Sales USD 8.37bln (exp. 8.31bln)
• Q4 Gardasil Sales USD 1.03bln (exp. 0.991bln)
• Q4 Winrevair Sales USD 467mln 

• FY EPS view 5.00-5.15 (exp. 5.27)
• FY Rev. view USD 65.5-67.0bln (exp. 67.4bln)

Merck & Co. reported a strong Q4 2025 with adjusted EPS and revenue exceeding expectations, particularly boosted by solid Keytruda and Gardasil sales. However, the guidance for FY EPS and revenue was below consensus, which may raise concerns about future growth prospects. The mixed signals suggest the market will focus on the strength of current sales against the potential for lower future performance.